Domů › Metastatický karcinom › Florida › Tampa
Klinické studie Metastatický karcinom v Tampa, FL
29 studií pro Metastatický karcinom hledá účastníky v lokalitách v Tampa a okolí (do cca 30 mil). Otevřete studii a zjistěte, kdo se může zapojit a jak kontaktovat tým studie.
Oficiální text studie (anglicky)
Hledáte účastníky pro studii? Zvýrazněte ji nahoře na této stránce – $99 na 30 dní →
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
Probíhá náborFáze 1/2
- Avenzo Therapeutics Recruiting Site, Tampa
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Probíhá náborFáze 1
- Moffitt Cancer Center, Tampa
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
Probíhá náborFáze 1
- ALX Center 7, Tampa
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Probíhá náborFáze 2/3
- Moffitt Cancer Center, Tampa
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
Probíhá náborFáze 1
- Moffitt Cancer Center, Tampa
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
Probíhá náborFáze 2
- Moffitt Cancer Center, Tampa
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Probíhá náborFáze 3
- Florida Cancer Specialists, Tampa
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Probíhá náborFáze 1
- Moffitt, Tampa
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Probíhá náborFáze 3
- Moffitt Cancer Center, Tampa
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Probíhá náborFáze 3
- Moffitt Cancer Center, Richard M. Shulze Family Foundation Outpatient Center, Tampa
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Probíhá náborFáze 1/2
- Moffitt Cancer Center and Research Institute, Tampa
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
Probíhá náborFáze 1/2
- Moffitt Cancer Center, Tampa
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
Probíhá náborFáze 1/2
- Avenzo Therapeutics Recruiting Site, Tampa
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
Probíhá náborFáze 1
- Moffitt Cancer Center, Tampa
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
Probíhá náborFáze 3
- Research Site, Tampa
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
Probíhá náborFáze 1
- Investigative Site #128, Tampa
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Probíhá náborFáze 1
- Moffitt Cancer Center, Tampa
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
Probíhá náborFáze 3
- Moffitt Cancer Center, Tampa
A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors
Probíhá náborFáze 1
- Exelixis Clinical Site #8, Tampa
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
Probíhá náborFáze 3
- Moffitt Cancer Center, Tampa
Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.
Probíhá náborFáze 2
- James A. Haley Veterans Administration Hospital, Tampa
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
Probíhá náborFáze 1
- Moffitt Cancer Center, Tampa
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Probíhá náborFáze 1
- Lee Moffitt Cancer Center, Tampa
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Probíhá náborFáze 1
- Moffitt Cancer Center, Tampa
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Probíhá náborFáze 1/2
- Moffitt Cancer Center, Tampa
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
Probíhá náborFáze 2/3
- Moffitt Cancer Center, Tampa
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
Probíhá náborFáze 3
- Moffitt Cancer Center, Tampa
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Probíhá náborObservační studie
- Massive Bio SYNERGY-AI site, Tampa
IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)
Probíhá náborFáze 1
- H. Lee Moffitt Cancer Center and Research Institute, Tampa
Studie Metastatický karcinom v jiných městech
- Houston, TX104 studií
- New York City, NY93 studií
- Nashville, TN70 studií
- Boston, MA63 studií
- Los Angeles, CA57 studií
- St. Louis, MO54 studií
- Arlington, VA53 studií
- Philadelphia, PA46 studií
- Chicago, IL45 studií
- San Antonio, TX44 studií
- Washington, DC43 studií
- Dallas, TX42 studií
Další studie v Tampa
- Nemalobuněčný plicní karcinom51 studií
- Rakovina prsu43 studií
- Rakovina (všechny typy)39 studií
- Kolorektální karcinom34 studií
- Akutní myeloidní leukemie29 studií
- Rakovina plic29 studií
- Rakovina slinivky břišní26 studií
- Rakovina vaječníků21 studií
- Melanom19 studií
- Myelodysplastické syndromy19 studií
- Rakovina prostaty18 studií
- Srdeční selhání18 studií
Zdroj: ClinicalTrials.gov, data načtena 6. 10. 2026. Každá studie má vlastní kritéria způsobilosti; o účasti rozhoduje tým studie.